Ensysce Biosciences, Inc. Common Stock
Compare this stock
ENSC Stock Report Card
$
28%
Performance
Score:
10/100
ENSC returned -96.40% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
25/100
ENSC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
Earnings
Score:
33/100
ENSC has missed earnings 3 times in the last 20 quarters.
Profit
Score:
27/100
Out of the last 20 quarters, ENSC has had 8 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
Score:
50/100
ENSC has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
Ensysce Biosciences, Inc. Common Stock Summary
Nasdaq / ENSC
Healthcare
Biotechnology
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
ENSC scored poorly on our reportcard. Here are some similar companies and how they performed.
